Key result
Porcine pulmonary valves are linked to ~63% lower MACE risk vs. bovine pericardial valves.
Why the study?
Do porcine bioprosthetic valves improve long-term event-free survival compared to bovine pericardial valves in patients with congenital heart disease undergoing surgical pulmonary valve replacement?
Cohort (n=231)
Yes
Do porcine bioprosthetic valves improve long-term event-free survival compared to bovine pericardial valves in patients with congenital heart disease undergoing surgical pulmonary valve replacement?
In patients with congenital heart disease undergoing surgical pulmonary valve replacement, porcine bioprostheses demonstrated superior long-term durability and a lower risk of major adverse cardiovascular events compared to bovine pericardial valves.
May warrant considering porcine valves for pulmonary replacement in adult congenital disease; leaves open need for randomized confirmation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Nogales et al. (2026) conducted a cohort in Congenital heart disease requiring surgical pulmonary valve replacement (n=231). Porcine bioprosthetic valves vs. Bovine pericardial bioprosthetic valves was evaluated on Composite of all-cause mortality, surgical or percutaneous reintervention on the pulmonary valve or conduit, and structural valve deterioration (MACE) (HR 0.37, 95% CI 0.16-0.83, p=0.015). Porcine bioprosthetic valves were associated with a significantly lower hazard of major adverse cardiovascular events compared with bovine pericardial valves (HR 0.37, p=0.015) during long-term follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: